Thymic stromal lymphopoietin expression is increased in nasal epithelial cells of patients with mugwort pollen sensitive-seasonal allergic rhinitis

Background Excessive expression of thymic stromal lymphopoietin （TSLP） has been demonstrated in asthmatic airway epithelia and in nasal epithelia from animal models of allergic rhinitis （AR）, but the evidence of expression of TSLP in nasal epithelial cells （NECs） of patients with AR is lacking. We aimed to investigate the expression of TSLP in NECs of patients with mugwort sensitive-seasonal AR and determine whether it is associated with severity of symptoms and the number of infiltrated eosinophils in nasal mucosa. Methods NECs specimens were obtained by scraping with plastic curettes from the nasal inferior turbinates of patients with mugwort pollen sensitive-seasonal AR （n=22） and nonallergic controls （n=11） during last peak mugwort pollen season. The severity of nasal symptom was assessed using a Visual Analog Scale （VAS）. In addition, serum mugwort pollen IgE levels were tested from each patient. In situ hybridization （ISH） was performed to test the messenger RNA （mRNA） of TSLP in the NECs. Furthermore, immunohistochemical staining （IHC） was scored to evaluate the expression of TSLP and eosinophil cell count was made by May-Grunwald/Giemsa staining. The correlation between expression of TSLP and all other parameters was analyzed in this study. Results The mRNA level of TSLP was significantly increased in NECs of patients with AR compared with the nonallergic control group （P 〈0.05）. In addition, IHC results showed that expression of TSLP in NECs from patients with AR was up-regulated which was correlated with VAS score （r=0.598; P 〈0.05） and nasal eosinophils count （r=0.702; P 〈0.05）, but it was unrelated with mugwort pollen specific IgE level. Conclusions These preliminary findings indicate a potential relationship between TSLP expression, severity of symptoms and nasal eosinophils count in pathogenesis of AR, but TSLP expression did not correlate with mugwort pollen specific IgE level. The elevated expression of TSLP might play a critical role in local atopical responses of AR. In the future, the TSLP has the potential to be one of the most important molecular markers for AR diagnoses and assessment.

艾蒿花粉诱导豚鼠过敏反应

目的:研究艾蒿花粉粗提物(MPE)和其主要成分之一artemisia vulgaris 1(Art V1)能否诱导豚鼠过敏反应,为艾蒿花粉过敏症研究建立动物模型。方法:艾蒿花粉粗提物或Art V1混悬于佐剂氢氧化铝凝胶中,每间隔10 d致敏豚鼠1次,共4次,然后以艾蒿花粉粗提物或Art V1抗原滴鼻诱发鼻炎症状。气道高反应性(AHR)、炎症细胞和肺组织病理的观察于Art V1气雾攻击5 d后,以乙酰甲胆碱(Mch)气雾吸入激发AHR,测定气道阻力和动态肺顺应性,计数和分类计数支气管肺泡灌洗液(BALF)中的炎症细胞,观察肺组织病理学改变。结果:Art V1组豚鼠在抗原激发下喷嚏次数和抓鼻次数显著增加,吸入Mch后气道阻力明显增加,动态肺顺应性明显降低,Mch气雾吸入可激发AHR;MPE组豚鼠喷嚏次数有所增加,气道反应性有所升高;两组BALF和病理切片均显示明显的嗜酸性粒细胞和中性粒细胞浸润。结论:艾蒿花粉粗提物和其主要成分Art V1均能诱导豚鼠过敏反应,Art V1致敏效果明显优于艾蒿粗提物。该模型的建立有利于过敏性疾病机制和治疗新药的研究。

艾蒿花粉变应原免疫治疗变应性鼻炎的疗效和安全性评估

目的回顾性评价艾蒿变应原制剂治疗艾蒿花粉过敏性鼻炎的疗效和安全性。方法回顾10年里接受艾蒿花粉变应原免疫治疗(SIT)的艾蒿花粉过敏性鼻炎患者,比较SIT治疗3年后过敏性鼻炎临床症状的严重程度,症状持续时间,治疗药物,皮肤点刺、艾蒿特异性IgE(specific IgE,sIgE)、总体自评和不良反应。结果 196例SIT治疗三年后,皮肤点刺试验的反应性较治疗前明显降低,血清sIgE水平显著降低。鼻炎症状总评分、药物积分差异均有统计学意义(P<0.001,Z=-7.524;P<0.001,Z=-6.012),89%总体自评为病情改善。9例患者发生全身不良反应。其中Ⅱ类7例次(泛发的荨麻疹)Ⅲ类2例次(泛发的荨麻疹合并血管性水肿)。所有患者总体自评均为明显改善,无致死性不良反应。结论使用艾蒿花粉变应原制剂可有效、安全地治疗艾蒿花粉过敏性鼻炎。

油菜花粉提取液蛋白质组份分析及其血清IgG抗体检测

目的 : 比较油菜花粉和蒿草花粉提取液蛋白质组份及免疫血清 ,探讨二者间有无共同抗原决定簇。方法 : 采用SDS PAGE电泳及考马斯亮蓝染色分析两种花粉蛋白质组份 ;用Dot ELISA交叉测定两种花粉豚鼠抗血清中IgG抗体。结果 : 油菜花粉显带 16条 ,分子量在 9～ 97kDa之间 ;蒿草花粉仅显带 6条 ,分子量在 11～ 6 7kDa之间。Dot ELISA检测发现两种花粉提取液均能与相应豚鼠抗血清发生反应 ,且两种花粉抗原与血清发生交叉反应。结论 : 油菜花粉与蒿草花粉提取液蛋白质组份差异较大 ,前者更复杂 ;但二者间存在共同抗原决定簇 ,可发生交叉过敏。

桃主要致敏蛋白Prup3T细胞表位鉴定

目的 Pru p 3是桃主要致敏蛋白,目前尚未见桃Pru p 3 T细胞表位在我国桃过敏反应中的研究,本研究探讨桃主要致敏蛋白Pru p 3 T细胞表位。方法纳入蒿花粉相关桃过敏患者20例和健康对照者10人,采集受检者的外周血单个核细胞(PBMC),将PBMC分别与8条Pru p 3来源的肽段共同孵育,比较桃过敏患者和健康对照者PBMC受各肽段刺激后的增生水平,分析不同肽段的变应原性。结果肽段Pru p 367-82对桃过敏患者PBMC的活化程度最高,20例桃过敏患者中对该肽段刺激指数(SI)阳性者14例,占70%; Pru p 323-38对桃过敏患者PBMC的活化率为55%(11/20)。Pru p 367-82与Art v 390-105氨基酸序列的一致率为81%。结论 Pru p 323-38和Pru p 367-82是引起我国桃过敏反应的主要T细胞表位,Pru p 367-82可能是参与蒿花粉-桃交叉反应的T细胞表位。